MERCK KGAA O.N.
-
EUR
(-)
- 15 min delayed data - Germany Stocks
| Open: | - |
| Change: | - |
| Volume: | - |
| Low: | - |
| High: | - |
| High / Low range: | - |
| Type: | Stocks |
| Ticker: | MRK |
| ISIN: | DE0006599905 |
MERCK KGAA O.N. news, videos and press releases
For more news please use our advanced search feature.
MERCK KGAA O.N. - More news...
MERCK KGAA O.N. - More news...
- 02/10/2025 - 19:06 EQS-Adhoc: Merck KGaA: Merck KGaA confirms discussions with Springworks Therapeutics, Inc. on potential acquisition
- 07/26/2024 - 16:50 EQS-Adhoc: Merck KGaA: Strong 2nd Quarter, Guidance raised
- 06/24/2024 - 17:00 EQS-Adhoc: Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued
- 12/05/2023 - 20:34 EQS-Adhoc: Merck KGaA: Phase III trial results for evobrutinib in relapsing multiple sclerosis did not meet primary endpoint of reducing annualized relapse rates (ARR) compared to oral teriflunomide
- 10/11/2023 - 16:06 EMD Electronics Celebrates Opening of New Arizona Factory, Contributing to the State's Growing Semiconductor Industry
- 05/30/2023 - 12:00 Merck KGaA, Darmstadt, Germany's New Barrier Materials Offer Superior Flexibility, Reliability, and Longer Lifetime in OLED Devices
- 05/15/2023 - 10:00 EMD Electronics Expands Renewable Energy Through Virtual Power Purchase Agreement With Recurrent Energy
- 04/12/2023 - 06:00 EMD Electronics Expands Semiconductor Manufacturing Capacities for the World's Largest Integrated Specialty Gases Facility in Hometown, Pennsylvania
- 11/03/2021 - 17:42 DGAP-Adhoc: Merck KGaA raises forecast for full year 2021
- 05/17/2021 - 12:00 Merck and BioMed X Institute Extend Collaboration to Continue Novel Research in Oncology and Autoimmunity
- 05/04/2021 - 18:36 DGAP-Adhoc: Merck KGaA raises forecast for full year 2021
- 03/16/2021 - 07:00 Merck KGaA, Darmstadt, Germany, Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer
- 01/20/2021 - 12:30 DGAP-Adhoc: Merck KGaA: Merck KGaA to discontinue bintrafusp alfa clinical trial (INTR@PID Lung 037)
- 09/29/2020 - 16:06 DGAP-Adhoc: Merck KGaA: Merck KGaA reverses provision for lawsuit in the amount of EUR 365 million
- 05/13/2020 - 23:40 /C O R R E C T I O N -- EMD Serono/
- 05/13/2020 - 22:27 Breakthrough Innovation in Cancer Care From EMD Serono Pipeline to Be Presented at ASCO 2020
- 11/20/2019 - 07:00 Merck KGaA, Darmstadt, Germany, Announces Orphan Drug Designation for Investigational Therapy Tepotinib in Patients with NSCLC Harboring MET Gene Alterations
- 09/23/2019 - 06:00 New Data at ESMO 2019 for Merck KGaA, Darmstadt, Germany, Highlight Focused Clinical Development and Commitment to Patient Care
- 09/11/2019 - 06:30 Merck KGaA, Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations
- 06/03/2019 - 14:25 Merck KGaA, Darmstadt, Germany Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with METex14 Skipping Mutations
- 02/27/2019 - 12:59 DGAP-Adhoc: Merck KGaA: Merck Proposes to Acquire Versum for USD 48 per Share and to Create a Leading Electronic Materials Player
- 02/05/2019 - 11:53 DGAP-Adhoc: Merck KGaA: Merck and GSK agree on Collaboration in Immuno-Oncology
- 01/24/2019 - 13:00 Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
- 12/21/2018 - 19:00 Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer
- 12/20/2018 - 12:42 Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon
- 12/10/2018 - 15:00 Merck KGaA, Darmstadt, Germany Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer
- 12/06/2018 - 13:00 Merck KGaA, Darmstadt, Germany, in Agreement with Cyclica for AI-augmented Screening Platform to Expand Research Capabilities
- 11/19/2018 - 12:12 Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
- 10/10/2018 - 06:00 Up to 10-Years of Follow-up Data Reaffirm Safety Profile of Investigational Cladribine Tablets
- 06/11/2018 - 12:30 Merck KGaA, Darmstadt, Germany Provides Update on Tepotinib Phase II Results in Advanced Hepatocellular Carcinoma
